IAN GRAGNOLATI: Open Payments
NPI 1689368466 · WEST HARTFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,134 in 44 payments from 11 companies in 2025. Trend: 2023 $472 · 2024 $519 · 2025 $1,134
Food & beverage: $1,134
| Company | Payments | Amount |
|---|---|---|
| LEO Pharma Inc. | 8 | $270 |
| GlaxoSmithKline, LLC. | 9 | $241 |
| ARS Pharmaceuticals Operations, Inc. | 10 | $218 |
| GENZYME CORPORATION | 8 | $217 |
| Genentech USA, Inc. | 2 | $40 |
| AstraZeneca Pharmaceuticals LP | 2 | $36 |
| CSL Behring | 1 | $28 |
| GC Biopharma USA, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $23 |
| Grifols USA, LLC | 1 | $17 |
Products named: NEFFY, DUPIXENT, NUCALA, ADBRY, ANZUPGO, TRELEGY ELLIPTA, Xolair, Andembry.
Industry payments across CT — which companies pay providers there.
